Some Life-Saving Treatments Still Exist Outside Basic Healthcare Access

Modern medicine can now do things that many families never imagined possible.

A drug can be designed to recognise a specific mutation in a specific tumour, then instruct the immune system to dismantle it with a precision that surgery alone could not achieve. A therapy can be engineered from a patient's own cells — extracted, reprogrammed, reinfused — with the goal of eliminating cancers that once carried very limited prognoses. Treatments that were described as experimental in medical literature a decade ago are now regarded, in the right clinical setting, as standard of care.

This is not science fiction. It is happening, quietly and incrementally, across oncology departments in leading hospitals around the world.

And yet.

For many families sitting in a consultant's office — in Bangkok, in Chiang Mai, in cities throughout Southeast Asia — the conversation about treatment rarely begins with "What is possible?" It increasingly begins with something far more difficult: "What is possible for us?"

That is the quiet shift this article is about.

The Gap Between Discovery and Access

The history of cancer medicine has always involved a lag between what becomes scientifically possible and what becomes broadly accessible. A new compound is discovered, then studied, then approved, then manufactured, then priced, then reimbursed — or not — and eventually reaches, or does not reach, the patient who needs it. That pipeline has always existed.

What has changed in the last decade is the speed and complexity of what is moving through it.

Immunotherapy — a broad category of treatments that work by modulating or activating the immune system against cancer cells — has transformed outcomes in melanoma, lung cancer, certain lymphomas, and a growing number of solid tumour types. The results, in eligible patients, can be profound. Some individuals who would have had limited options under older treatment protocols are experiencing sustained remissions.

Targeted therapy takes a more precise approach: identifying specific molecular drivers of a particular tumour — gene mutations, protein overexpression, receptor abnormalities — and deploying drugs designed to interfere with those exact mechanisms. Unlike traditional chemotherapy, which broadly attacks dividing cells, targeted agents are engineered to be selective. The efficacy in the right patient, with the right mutation, can be substantial.

Precision medicine is the philosophy behind both. Genetic testing — including comprehensive genomic profiling — allows oncologists to understand the molecular fingerprint of a patient's cancer and design a treatment strategy around that specific biology, rather than applying a protocol based on the cancer's anatomical origin alone.

And then there is CAR-T therapy: a technology in which a patient's own T-cells are extracted, genetically engineered in a laboratory to express receptors capable of identifying cancer cells, and reinfused into the bloodstream as a living, targeted treatment. For certain blood cancers that have not responded to other therapies, CAR-T represents something that was not previously possible. It is also, by any reasonable measure, one of the most complex and expensive medical interventions ever developed.

Biologics — large-molecule therapies derived from living systems — extend into rheumatology, gastroenterology, and other specialties beyond oncology. But within cancer care, they increasingly intersect with immunotherapy and targeted treatments.

All of these represent genuine progress. The science is real. The outcomes, in appropriate patients, are meaningful. The clinical literature is substantive.

The access problem, however, is equally real.

What Access Actually Means

When healthcare professionals and economists use the word "access," they mean something specific: the ability of a patient to receive a given treatment in a timely manner, without prohibitive financial consequence, within their existing healthcare system.

By that definition, access to many modern oncological therapies in Thailand — and across much of Southeast Asia — remains genuinely constrained, even for patients who can afford private care.

There are several layers to this.

Reimbursement limitations. The National List of Essential Medicines in Thailand, which forms the backbone of what the Universal Coverage Scheme will fund, does not include most novel targeted therapies, immunotherapies, or biologic agents. The approval and reimbursement process for new drugs in any national health system involves cost-effectiveness assessments, budget impact analyses, and negotiations with pharmaceutical manufacturers. That process takes time — often years — and not all treatments make it through.

A therapy that receives regulatory approval from the FDA or EMA does not automatically become reimbursable under a national health scheme. In many cases, it never does, or it does so with significant restrictions on which patients qualify.

Eligibility criteria. Even within private insurance coverage, treatment eligibility is rarely unconditional. Policies may cover chemotherapy as a broad category while excluding specific targeted agents. Critical illness riders may pay out a lump sum upon diagnosis but place no obligation on that payment to be sufficient to cover multi-year treatment. Biological and targeted therapies may be excluded entirely or subject to prior authorisation processes that require documented treatment failure on less expensive alternatives first.

Imported medication costs. Many newer cancer drugs are not manufactured domestically in Thailand. Import costs, logistics, and limited market volumes contribute to prices that can be substantially higher than in countries where volume purchasing drives unit costs down. A targeted therapy that costs a patient a modest sum in Germany or the United Kingdom — after government reimbursement — may represent several hundred thousand baht per treatment cycle in Thailand without coverage.

Waiting periods and treatment sequencing. In some cases, access is not simply about cost but about the practical realities of obtaining a treatment: availability at a given institution, waiting lists at specialist centres, the time required for genetic profiling results, the logistics of obtaining drugs not stocked in standard hospital pharmacies.

Geographic concentration of expertise. Precision oncology requires more than the drug itself. It requires molecular pathology capabilities for accurate biomarker testing, specialist oncologists with expertise in interpreting genomic profiles, multidisciplinary tumour boards, and support infrastructure. These resources are concentrated, in Thailand as elsewhere, in a small number of major academic and private hospital centres. For patients outside Bangkok or the major provincial cities, the practical distance from specialist care adds another layer of complexity.

None of this is a criticism of any particular system. Every national healthcare framework operates under genuine resource constraints, and the cost of novel cancer therapies — often priced at millions of baht per patient per year — represents a genuine challenge for any public health budget. The point is not that systems are failing. The point is that families planning their financial continuity need to understand the gap between what medicine can do and what their existing coverage is likely to fund.

The Emotional Landscape of Treatment Decisions

There is an aspect of this conversation that financial planning rarely addresses directly, but which shapes the experience of every family who encounters it.

When a serious diagnosis arrives, the emotional response is immediate and overwhelming. What follows — the gathering of information, the consultation of specialists, the weighing of options — takes place under conditions of profound psychological stress. Decisions about treatment are made not in calm analytical conditions but in a state of acute urgency, grief, and fear.

In this environment, families often encounter something that was not part of their mental model of how illness works.

They had assumed — reasonably, given how healthcare is commonly discussed — that treatment decisions were primarily medical. That the doctor would determine the best course, and the patient would receive it. The idea that financial capacity could meaningfully constrain which treatments were available, or how quickly they could begin, is one that many families encounter for the first time at exactly the moment they are least equipped to process it.

This is not a failure of character. It is a failure of preparation, and it is entirely understandable. The conversation about healthcare innovation and financial readiness is rarely had before it is urgently needed.

The emotional reality that many families describe is a specific kind of helplessness: not the helplessness of facing illness itself, but the helplessness of knowing that a treatment exists, that it may be appropriate for their family member, and that accessing it requires navigating a set of financial, logistical, and bureaucratic barriers that they had not anticipated and are not prepared for.

One of the central contributions that thoughtful financial planning can make is simply to remove, in advance, as many of those barriers as possible — so that treatment decisions can be made on clinical grounds, not financial ones.

The Speed of Innovation and the Stillness of Financial Plans

Medicine is moving quickly.

Genetic profiling technologies that once took weeks and cost tens of thousands of dollars can now produce results in days. Liquid biopsy — the analysis of circulating tumour DNA from a blood sample — is beginning to allow tumour monitoring without invasive tissue sampling. Treatment protocols in oncology are being revised not on the decadal timescale of the past but on cycles of two to four years, as new trial data reshapes clinical consensus.

The approval of a major immunotherapy combination, the publication of a landmark Phase III trial, the expanded indication of a targeted agent to a new cancer type — these events are happening regularly, continuously updating the standard of care for different diagnoses.

Financial plans, by contrast, tend to be relatively static.

A critical illness policy purchased ten years ago was designed around the treatment landscape of that time. The sum insured was calculated in relation to the costs and therapies that existed then. Ten years later, the cancer that policy was designed to cover may now have a targeted therapy available — one that the policy does not specify, that the insurer has not updated its definitions to include, and that costs three times what the original benefit was intended to address.

This is not primarily a criticism of insurance products. Insurance products are actuarially designed and priced against knowable risk profiles. The emergence of novel therapies represents exactly the kind of structural change that is difficult to price in advance.

It is, however, a fundamental planning consideration.

When someone asks whether their financial protection is adequate, the relevant question is not only "is the sum insured sufficient for the conditions I know about today?" but also "is it likely to remain sufficient against the treatment landscape that will exist if I become seriously ill in ten or twenty years?"

The honest answer, for most policies purchased more than a decade ago, is that this has not been formally evaluated.

Biologics, Imported Drugs, and the Cost of Precision

It is worth being specific about costs, not to cause alarm but to provide grounding.

Biological therapies — a category that includes many targeted cancer drugs — are inherently expensive to produce. Unlike small-molecule drugs synthesised through straightforward chemical processes, biologics are derived from living cells and require sophisticated manufacturing infrastructure, extensive quality controls, and cold-chain logistics. The development costs are substantial. The manufacturing complexity is real.

In markets where biosimilar competition has developed — generic equivalents of biologic drugs that have come off patent — prices have moderated. In markets where that competition does not exist, prices remain at originator levels.

Thailand is not a large enough pharmaceutical market to attract the volume-pricing dynamics that reduce biologic costs in North America or Western Europe. Many targeted cancer therapies are available at private hospitals but at import prices that reflect a relatively thin domestic market.

Illustratively — and these are broad ranges, not precise quotations, as prices vary by drug, institution, and regimen — monthly costs for certain targeted therapies can range from 80,000 to 400,000 baht. Immunotherapy cycles, which may be administered every three to six weeks for extended periods, can carry similar or higher per-cycle costs. CAR-T therapy, where available, involves not only the cost of the treatment itself but the infrastructure of a centre capable of administering it — and total treatment costs in global markets have been documented in the millions of dollars per patient.

Families who have planned for a serious illness based on a critical illness payout of one to two million baht may find, in the event of a diagnosis where novel therapies are relevant, that the financial cushion they believed they had is substantially thinner than the treatment landscape requires.

This is not a catastrophe that has no preparation. But preparation requires acknowledging that it exists.

Planning for the Treatments That Don't Exist Yet

There is a further dimension to this conversation that touches on genuine uncertainty.

Some of the treatments that will be considered standard of care in fifteen years are currently in Phase II clinical trials. Some are in early-phase research. Some have not yet been conceived.

Financial planning has no reliable mechanism for accounting for this explicitly. No product can be engineered to perfectly track medical inflation or therapeutic innovation. What planning can do is build in margin — sufficient coverage, regularly reviewed, designed to account for the probability that the treatment landscape in 2040 will be as different from today as today's is from 2010.

The families who are likely to navigate a serious illness with the most financial stability are not necessarily those with the largest insurance policies. They are those whose protection has been designed thoughtfully, reviewed regularly, and structured with an understanding that healthcare costs — and particularly the costs of advanced, precise, or novel treatments — are not stable.

This includes thinking about treatment abroad. For some advanced therapies where domestic access is limited — certain cell therapies, early clinical trial access, specialist surgical procedures — families may need to consider care in Singapore, Japan, South Korea, or further afield. International treatment adds not only the cost of the therapy itself but travel, accommodation, absence from work, and the logistical complexity of managing ongoing care across borders.

A financial plan that accounts only for domestic treatment costs may be incomplete for a family that would, in the event of a serious diagnosis, consider any option that offered meaningful clinical hope.

What Continuity Planning Looks Like Here

The PEDNOII perspective on this is straightforward: continuity planning is increasingly inseparable from healthcare access planning.

To plan for financial continuity is to plan for the realistic possibility that someone in your family may, at some point in their life, face a diagnosis where the most appropriate treatment is expensive, not automatically covered, and requires decisions to be made quickly under significant emotional pressure.

The questions worth sitting with — not today in a moment of crisis, but in a period of relative calm — are:

If someone in my household received a diagnosis tomorrow where the recommended treatment was a targeted biologic agent at 150,000 baht per month, for two years, what would we do?

If the treatment we needed was not available within the public system and required private access, or access abroad, how would we fund that without selling assets we cannot afford to lose?

If the critical illness coverage we have was purchased a decade ago and has never been reviewed, does it still reflect the cost of care that exists today?

These are not comfortable questions. They are also not unanswerable ones. And answering them in a period of calm is substantially more valuable than confronting them for the first time under duress.

A Final Observation

Modern medicine has made genuine and remarkable progress. The emergence of immunotherapy, targeted therapy, and precision oncology represents one of the most significant shifts in cancer care in generations. For many patients, these advances have meaningfully changed what is possible.

The challenge for families is not that this progress exists. The challenge is that access to it is not uniform, not automatic, and not guaranteed by the protection structures that most families currently have in place.

The question that an increasing number of families are asking — quietly, in consultation rooms, in financial planning conversations, in late-night conversations that are never shared publicly — is not "does treatment exist?"

It is: "Can we get to it? Can we afford it? Can we sustain it? And what do we do if we can't?"

Planning, thoughtfully and in advance, is how those questions get answered before they become urgent.

Medicine's most significant advances often arrive quietly — in a journal, in a trial result, in a treatment protocol update. What does not arrive quietly is the moment when a family discovers that what they need exists, but that accessing it is another question entirely. The gap between what medicine can do and what a family can realistically reach is not inevitable — but closing it requires planning that was done before the need arrived.